Sophy Company

Kochi, Japan

Sophy Company

Kochi, Japan

Time filter

Source Type

Le T.H.,Institute of Biotechnology | Le T.B.,Institute of Biotechnology | Doan T.H.T.,Institute of Biotechnology | van Quyen D.,Institute of Biotechnology | And 5 more authors.
Journal of Microbiology and Biotechnology | Year: 2011

Avian influenza virus vaccines produced in oil-emulsified inactivated form with antigen content of at least 160 hemagglutinin units (HAU) induced immunity in birds. However, in addition to enhancing the effect of the adjuvant(s), other additional supplemented biological compounds included in inactivated vaccines could produce higher levels of antibody. We examined in chickens, Vietnamese ducks, and muscovy ducks the adjuvant effect of Sophy β-glucan (SBG), a β-1,3-1,6 glucan produced by the black yeast Aureobasidium pollulans strain AF0-202, when administered with an avian influenza H5 subtype vaccine. In Experiment 1, 40 chickens (ISA Brown hybrid), allocated to four groups of ten each, were immunized with Oil-H5N1(VN), Oil-H5N1(CN), Oil-H5N2(CN), and saline (control group), respectively. In Experiment 2, chickens (ISA Brown hybrid), muscovy ducks (French hybrid), and Vietnamese ducks (indigenous Vietnamese) were used to further assess the effect of SBG on immunogenicity of the Oil-H5N1(VN) Vietnamese vaccine. ELISA and hemagglutination inhibition (HI) assays were used to assess the antibody response. The H5 subtype vaccines initiated significantly higher immune responses in the animals dosed with SBG, with 1.0-1.5 log2 higher HI titers and 10-20% ELISA seroconversion, compared with those not dosed with β-glucan. Notably, some of the animals dosed with SBG induced HI titers higher than 9.0 log2 following boosting immunization. Taken together, our serial studies indicated that SBG is a potential effector, such as enhancing the immune response to the H5 vaccines tested.


Le T.H.,Institute of Biotechnology | Le K.X.T.,Institute of Biotechnology | Cuong P.V.,Institute of Biotechnology | Cuc N.T.K.,Institute of Biotechnology | And 3 more authors.
Tropical Medicine and Health | Year: 2010

Sophy β-glucan, a type of β-1,3-1,6 glucan produced by a black yeast Aureobasidium pollulans strain AF0-202, is currently approved for use as a health food supplement. The new genotypic avian influenza H5N1 is one of the major emerging infectious diseases causing concern and loss in Vietnam, Asian and several European countries during the 2003-2008 period. We examined the effect of Sophy β-glucan on the immune response against the new H5N1 vaccine made in Vietnam/China and H5N2 made in China. As a result, both H5N1 and H5N2 vaccines elicited a significantly high immune response with Sophy β-glucan supplied in drinking water in all the mice tested (2-3 log2 higher HI titer). These vaccines also elicitated ELISA positivity (ELISA (+): seroconversion) 10-20% higher than those used in groups vaccinated without Sophy β-glucan. We conclude that Sophy β-glucan showed an excellent adjuvant effect on H5N1 and H5N2 vaccinations in a mouse model. © 2010 by The Japanese Society of Tropical Medicine.

Loading Sophy Company collaborators
Loading Sophy Company collaborators